12
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A 3-mRNA-based prognostic signature of survival in oral squamous cell carcinoma

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Oral squamous cell carcinoma (OSCC) is the most common type of head and neck squamous cell carcinoma with an unsatisfactory prognosis. The aim of this study was to identify potential prognostic mRNA biomarkers of OSCC based on analysis of The Cancer Genome Atlas (TCGA).

          Methods

          Expression profiles and clinical data of OSCC patients were collected from TCGA database. Univariate Cox analysis and the least absolute shrinkage and selection operator Cox (LASSO Cox) regression were used to primarily screen prognostic biomarkers. Then multivariate Cox analysis was performed to build a prognostic model based on the selected prognostic mRNAs. Nomograms were generated to predict the individual’s overall survival at 3 and 5 years. The model performance was assessed by the time-dependent receiver operating characteristic (ROC) curve and calibration plot in both training cohort and validation cohort ( GSE41613 from NCBI GEO databases). In addition, machine learning was used to assess the importance of risk factors of OSCC. Finally, in order to explore the potential mechanisms of OSCC, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis was completed.

          Results

          Three mRNAs ( CLEC3B, C6 and CLCN1) were finally identified as a prognostic biomarker pattern. The risk score was imputed as: (−0.38602 × expression level of CLEC3B) + (−0.20632 × expression level of CLCN1) + (0.31541 × expression level of C6). In the TCGA training cohort, the area under the curve (AUC) was 0.705 and 0.711 for 3- and 5-year survival, respectively. In the validation cohort, AUC was 0.718 and 0.717 for 3- and 5-year survival. A satisfactory agreement between predictive values and observation values was demonstrated by the calibration curve in the probabilities of 3- and 5- year survival in both cohorts. Furthermore, machine learning identified the 3-mRNA signature as the most important risk factor to survival of OSCC. Neuroactive ligand-receptor interaction was most enriched mostly in KEGG pathway analysis.

          Conclusion

          A 3-mRNA signature ( CLEC3B, C6 and CLCN1) successfully predicted the survival of OSCC patients in both training and test cohort. In addition, this signature was an independent and the most important risk factor of OSCC.

          Related collections

          Most cited references25

          • Record: found
          • Abstract: found
          • Article: not found

          XGBoost Model for Chronic Kidney Disease Diagnosis

          Chronic Kidney Disease (CKD) is a menace that is affecting 10 percent of the world population and 15 percent of the South African population. The early and cheap diagnosis of this disease with accuracy and reliability will save 20,000 lives in South Africa per year. Scientists are developing smart solutions with Artificial Intelligence (AI). In this paper, several typical and recent AI algorithms are studied in the context of CKD and the extreme gradient boosting (XGBoost) is chosen as our base model for its high performance. Then, the model is optimized and the optimal full model trained on all the features achieves a testing accuracy, sensitivity, and specificity of 1.000, 1.000, and 1.000, respectively. Note that, to cover the widest range of people, the time and monetary costs of CKD diagnosis have to be minimized with fewest patient tests. Thus, the reduced model using fewer features is desirable while it should still maintain high performance. To this end, the set-theory based rule is presented which combines a few feature selection methods with their collective strengths. The reduced model using about a half of the original full features performs better than the models based on individual feature selection methods and achieves accuracy, sensitivity and specificity, of 1.000, 1.000, and 1.000, respectively.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The role of complement in tumor growth.

            Complement is a central part of the immune system that has developed as a first defense against non-self cells. Neoplastic transformation is accompanied by an increased capacity of the malignant cells to activate complement. In fact, clinical data demonstrate complement activation in cancer patients. On the basis of the use of protective mechanisms by malignant cells, complement activation has traditionally been considered part of the body's immunosurveillance against cancer. Inhibitory mechanisms of complement activation allow cancer cells to escape from complement-mediated elimination and hamper the clinical efficacy of monoclonal antibody-based cancer immunotherapies. To overcome this limitation, many strategies have been developed with the goal of improving complement-mediated effector mechanisms. However, significant work in recent years has identified new and surprising roles for complement activation within the tumor microenvironment. Recent reports suggest that complement elements can promote tumor growth in the context of chronic inflammation. This chapter reviews the data describing the role of complement activation in cancer immunity, which offers insights that may aid the development of more effective therapeutic approaches to control cancer.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Chloride channels in cancer: Focus on chloride intracellular channel 1 and 4 (CLIC1 AND CLIC4) proteins in tumor development and as novel therapeutic targets.

              In recent decades, growing scientific evidence supports the role of ion channels in the development of different cancers. Both potassium selective pores and chloride permeabilities are considered the most active channels during tumorigenesis. High rate of proliferation, active migration, and invasiveness into non-neoplastic tissues are specific properties of neoplastic transformation. All these actions require partial or total involvement of chloride channel activity. In this context, this class of membrane proteins could represent valuable therapeutic targets for the treatment of resistant tumors. However, this encouraging premise has not so far produced any valid new channel-targeted antitumoral molecule for cancer treatment. Problematic for drug design targeting ion channels is their vital role in normal cells for essential physiological functions. By targeting these membrane proteins involved in pathological conditions, it is inevitable to cause relevant side effects in healthy organs. In light of this, a new protein family, the chloride intracellular channels (CLICs), could be a promising class of therapeutic targets for its intrinsic individualities: CLIC1 and CLIC4, in particular, not only are overexpressed in specific tumor types or their corresponding stroma but also change localization and function from hydrophilic cytosolic to integral transmembrane proteins as active ionic channels or signal transducers during cell cycle progression in certain cases. These changes in intracellular localization, tissue compartments, and channel function, uniquely associated with malignant transformation, may offer a unique target for cancer therapy, likely able to spare normal cells. This article is part of a special issue itled "Membrane Channels and Transporters in Cancers."
                Bookmark

                Author and article information

                Contributors
                Journal
                PeerJ
                PeerJ
                peerj
                peerj
                PeerJ
                PeerJ Inc. (San Diego, USA )
                2167-8359
                31 July 2019
                2019
                : 7
                : e7360
                Affiliations
                [1 ]Department of Prosthodontics, Xiangya Stomatological Hospital & School of Stomatology, Central South University , Changsha, China
                [2 ]Department of Endodontics, Xiangya Stomatological Hospital & School of Stomatology, Central South University , Changsha, China
                [3 ]Department of Stomatology, The Second Xiangya Hospital, Central South University , Changsha, China
                [4 ]Department of Stomatology, Xiangya Hospital, Central South University , Changsha, China
                Article
                7360
                10.7717/peerj.7360
                6679650
                31396442
                0f1a5951-229a-4de2-a852-63f418f18945
                ©2019 Cao et al.

                This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.

                History
                : 6 March 2019
                : 26 June 2019
                Funding
                The authors received no funding for this work.
                Categories
                Bioinformatics
                Dentistry
                Oncology

                bioinformatics,mrna,prognosis,oral squamous cell carcinoma

                Comments

                Comment on this article